CPIC abacavir & HLA-B guideline update published

CPIC has extensively reviewed the literature and concluded no changes are required to the therapeutic recommendations of the abacavir dosing guideline based on HLA-B genotype since the original publication in 2012.

The 2014 update includes the following additions:

• Clinical implementation resources to help implementation of the guidelines into an Electronic Heath Record (EHR), including design of clinical decision support (CDS) alerts. 
• Abacavir recommendations based on HLA-B*57:01 in pediatrics.
• Additional supporting studies.
• Discussion on recent studies regarding the mechanism of abacavir-induced hypersensitivity in HLA-B*57:01 individuals. 

View the interactive CPIC abacavir dosing guidelines based on HLA-B genotype, with the available full update and original published guidelines.


Read the article:
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.
Michael A. Martin, James M. Hoffman, Robert R. Freimuth, Teri E. Klein, Betty J. Dong, Munir Pirmohamed, J. Kevin Hicks, Mark R. Wilkinson, David W. Haas and Deanna L. Kroetz. Clinical Pharmacology & Therapeutics accepted article preview online 21 February 2014; doi:10.1038/clpt.2014.38